DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Omni Shoreham Hotel

2019 年 01 月 28 日 7:00 上午 - 2019 年 01 月 30 日 3:00 下午

2500 Calvert Street NW, , Washington, DC 20008 , USA

Pharmacovigilance and Risk Management Strategies Conference

NEW! The 2019 meeting will be a full three days, allowing maximum learning opportunities!

Session 14: Hot Topics

Session Chair(s)

Mick  Foy

Mick Foy

Director of Delivery

Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

This session will inform attendees about the 3S project. Funded by the Bill and Melinda Gates the WHO are working with low and middle income countries with a high disease burden in specific areas that are subject to new treatments to increase their pharmacovigilance capabilities. MHRA are collaborating in the project to ensure regulatory pharmacovigilance capacity is increased to collect, analyse and act on safety data.

Learning Objective : Upon completion of this session, the participant should be able to:
    Understand the rationale for 3S
  • Learn how industry is key to the success of PV in low- and middle-income countries
  • Understand the need for robust regulatory frameworks for PV

Speaker(s)

Mick  Foy

Mick Foy

Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Director of Delivery

Raj  Long, MEd, MSc

Triple-s (3S) Smart Safety Surveillance

Raj Long, MEd, MSc

Bill and Melinda Gates Foundation, United Kingdom

Deputy Director, Safety and Pharmacovigilance

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。